Abstract
Mu and kappa opioid agonists are known to produce different, and sometimes opposite, effects on several pharmacological and behavioral measures. However, whetherkappa agonists can be used to antagonize the reinforcing and putative dopamine (DA)-releasing properties of a muagonist such as heroin is unclear. With the use of the high temporal and spatial resolution of in vivo fast-cyclic voltammetry to measure changes in extracellular DA in the nucleus accumbens (NAcc), we observed (1) dose-dependent increases in DA in the NAcc during heroin self-administration (SA), (2) that coadministration of the kappa agonist U50,488H with heroin or intracerebroventricular dynorphin A pretreatment significantly depressed the heroin-stimulated DA release during SA, where U50,488H alone inhibited the basal DA release in the NAcc, (3) that coadministration of low-dose U50,488H or dynorphin A significantly increased heroin SA behavior, whereas high-dose U50,488H, which alone did not support SA behavior, reduced or completely blocked heroin SA and (4) that nor-binaltorphimine dihydrochloride (a selectivekappa receptor antagonist) potentiated DA release in the NAcc and modestly decreased heroin SA. Taken together, these data suggest that endogenous kappa receptor activation can inhibit mu agonist-induced activation of the mesolimbic DA pathway, which may in turn depress heroin-induced reinforcement.
Footnotes
-
Send reprint requests to: Elliot A. Stein, Ph.D., Department of Psychiatry, 8701 Watertown Plank Road, Milwaukee, WI 53226. E-mail: estein{at}mcw.edu
-
↵1 This work was supported in part by United States Public Health Service Grant DA09465 (E.A.S.) and NIDA/INVEST Fellowship N01DA-3–0002 (Z.-X.X.).
- Abbreviations:
- FCV
- fast cyclic voltammetry
- DAMGO
- [d-Ala2,N-MePhe4,Gly-ol5]enkephalin
- SA
- self-administration
- VTA
- ventral tegmental area
- NAcc
- nucleus accumbens
- DA
- dopamine
- AA
- ascorbic acid
- DOPAC
- dihydroxyphenylacetic acid
- U50
- U50,488H
- DynA
- dynorphin A(1–17)
- nor-BNI
- nor-binaltorphimine dihydrochloride
- i.c.v.
- intracerebroventricular
- GABA
- γ-aminobutyric acid
- Received March 10, 1997.
- Accepted September 19, 1997.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|